In a report released today, Suraj Kalia from Northland Securities maintained a Hold rating on Edwards Lifesciences (NYSE: EW), with a price target of $120. The company’s shares opened today at $140.
Kalia wrote:
“We analyze data on MitraClip + GDMT in HFpEF / HFrEF + FMR, & impact on existing clinical trials in both transcatheter mitral repair / replacement programs. There are a ton of unknowns, however, it is likely that: 1) Edwards PASCAL trial will need to be redesigned with MitraClip as the control (even though the trial is in DMR; Medtronic’ APOLLO trial, especially in HFrEF “might” not need MitraClip as the comparator). 2) COAPT results are not applicable in real-world setting. Key Points We confess, we don’t have access to raw data in COAPT, hence it is impossible to make definitive arguments.”
According to TipRanks.com, Kalia is a 5-star analyst with an average return of 13.4% and a 61.5% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Apollo Endosurgery Inc, and Irhythm Technologies.
Edwards Lifesciences has an analyst consensus of Moderate Buy, with a price target consensus of $161, a 15.0% upside from current levels. In a report issued on October 2, Guggenheim also downgraded the stock to Hold.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $175 and a one-year low of $100.20. Currently, Edwards Lifesciences has an average volume of 1.43M.
Based on the recent corporate insider activity of 106 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. It operates through the following geographical segments: United States, Europe, Japan, and Rest of the World. Its products are categorized into three areas: Surgical Heart Valve Therapy, Transcatheter Heart Valves, and Critical Care.
